News | November 24, 2014

Early Detectable Vascular Disease Linked to Erectile Dysfunction

CT calcium exam could indicate risk of developing erectile dysfunction

November 24, 2014 — Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don’t have early-stage vascular disease, according to research presented at the American Heart Association’s (AHA) Scientific Sessions 2014. Data suggests use of a coronary computed tomography (CT) calcium exam may reveal the patient’s risk of developing erectile dysfunction.

“Erectile function can be a window into men’s cardiovascular and overall health,” said David I. Feldman, B.S., lead author and research assistant at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins in Baltimore, Maryland. “Erectile dysfunction and cardiovascular disease commonly co-exist.”

Researchers studied 1,862 men without existing heart disease and assessed the relationship between early atherosclerotic plaque development and arterial stiffness and dysfunction with their subsequent self-reporting of erectile dysfunction.

“We looked at which measurement of early vascular disease was the best predictor for erectile dysfunction,” Feldman said. “We also looked at whether those men with multiple abnormalities, such as increased plaque in addition to arterial stiffness and dysfunction, were more likely to also suffer from erectile dysfunction.”

Researchers found:

  • Men with coronary artery calcium scores greater than 100 Agatston units were 43 percent more likely to later self-report erectile dysfunction compared to otherwise identical men with normal calcium scores. (The Agatston Score is a measure of the amount of calcified plaque in the coronary arteries.)
  • Men who subsequently had erectile dysfunction were at least two times more likely to have coronary artery calcium scores greater than 100 Agatston units at the start of the study, which ran more than nine years.
  • While coronary artery calcium had the strongest association to erectile dysfunction, other measures of early vascular disease, including carotid intima-media thickness (cIMT), were notably worse among men with erectile dysfunction compared to those without. cIMT measures plaque build-up in your carotid arteries that supply blood to the head, neck, and brain.
  • After considering age, race, sex and traditional risk factors — such as diabetes, smoking, high cholesterol and obesity — men with abnormalities of both atherosclerosis as well arterial stiffness and dysfunction were 53 percent more likely to later self-report erectile dysfunction.


To improve long-term erectile function and reduce the risk for worsening cardiovascular health, at-risk men should eat a heart-healthy diet, engage in physical activity and avoid smoking, Feldman said.

“Current guidelines recommend exercise stress testing and an ankle-brachial index test for risk assessment in patients with erectile dysfunction,” he said. “Our results suggest a more powerful indicator is direct measurement of coronary plaque through the use of a CT coronary artery calcium test.”

More research is needed before physicians routinely use coronary artery calcium tests over other noninvasive methods to assess men’s sexual health, Feldman said. And more work needs to be done on how best to prevent erectile dysfunction in those men with confirmed asymptomatic vascular disease.

Researchers excluded men on impotence drugs and couldn’t ensure that all men were free of erectile dysfunction at the study’s baseline examination.

Co-authors are Kevin L. Billups, M.D.; Andrew P. DeFilippis, M.D.; Kanchan Chitaley, Ph.D.; Philip Greenland, M.D.; James H. Stein, M.D.; Matthew J. Budoff, M.D.; Zeina Dardari, M.S.; Roger S. Blumenthal, M.D.; Khurram Nasir, M.D., M.P.H.; and Michael J. Blaha, M.D., M.P.H. Author disclosures are on the abstract.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init